Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 12/14/2025 By Sneha ShahDecember 16, 2025
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 11/16/2025 By Casper MillerNovember 19, 2025
Leveraged & Inverse Content Hub As M&A Deals Rise, Can Biotech Pharma Break Loose? By Ben HernandezSeptember 19, 2025
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 08/17/2025 By Sneha ShahAugust 19, 2025
Leveraged & Inverse Content Hub CURE: Make an Adventurous Bet on an Undervalued Sector By Todd ShriberAugust 12, 2025
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 07/28/2024 By Sneha ShahJuly 30, 2024
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 07/14/2024 By Sneha ShahJuly 16, 2024
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 02/18/2024 By Sneha ShahFebruary 21, 2024
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 09/11/2022 By Sneha ShahSeptember 13, 2022
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 06/26/2022 By Sneha ShahJune 29, 2022
Leveraged & Inverse Content Hub Top Performing Leveraged/Inverse ETFs: 11/07/2021 By Sneha ShahNovember 9, 2021
Leveraged & Inverse Content Hub 3 ETFs to Access a Changing Pharmaceutical Industry By Ben HernandezAugust 16, 2021
Leveraged & Inverse Content Hub PILL Hasn’t Been a Bitter ETF to Swallow The Past Month By Ben HernandezDecember 23, 2020
Leveraged & Inverse Content Hub Direxion to Change Indexes For Leveraged Pharma, Real Estate ETFs By Todd ShriberJune 4, 2019
Beyond Basic Beta Content Hub 4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat By Ben HernandezApril 9, 2019
